Bioorganic and Medicinal Chemistry p. 2115 - 2137 (2004)
Update date:2022-08-05
Topics:
Takami, Atsuya
Iwakubo, Masayuki
Okada, Yuji
Kawata, Takehisa
Odai, Hideharu
Takahashi, Nobuaki
Shindo, Kazutoshi
Kimura, Kaname
Tagami, Yoshimichi
Miyake, Mika
Fukushima, Kayoko
Inagaki, Masaki
Amano, Mutsuki
Kaibuchi, Kozo
Iijima, Hiroshi
Several structurally unrelated scaffolds of the Rho kinase inhibitor were designed using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. A docking simulation using the ligand-binding pocket of the Rho kinase model helped to comprehensively understand and to predict the structure-activity relationship of the inhibitors. This understanding was useful for developing new Rho kinase inhibitors of higher potency and selectivity. We identified several potent platforms for developing the Rho kinase inhibitors, namely, pyridine, 1H-indazole, isoquinoline, and phthalimide.
View MoreSEA BRGIHT INDUSTRY CO.,LIMITED
Contact:0086 755 8622 3990
Address:Rm 17B3,GuangCaiXinTianDi Bldg,GuiMiao Rd,NanShan District,Shenzhen,China
Contact:(1) 206-3550089
Address:5115 NE 8TH PL, Renton, WA 98059 USA
HUNAN CHEMAPI BIOLOGICAL TECHNOLOGY CO.,LTD.
Contact:+86-186-02659358
Address:1004, building 3, Wanke Jinsemaitianyuan, 498 Guitang Road, Yuhua District, Changsha City, Hunan Province, China
puyang hongda shengdao new material co.,ltd.
Contact:+86-393- 4896278
Address:No.29 East Zhongyuan Road
Dongying J&M Chemical Co., Ltd,
Contact:546-8551108
Address:Room 1219, Zisheng Mansion, Zibo Road, Dongying, Shandong, China
Doi:10.1007/BF01431320
(1996)Doi:10.1039/dt9960002857
(1996)Doi:10.1002/adsc.201500255
(2015)Doi:10.1016/0957-4166(96)00232-7
(1996)Doi:10.1021/ja304816e
(2012)Doi:10.1021/jo0300035
(2003)